Pancreatic neuroendocrine tumours (PNETs) are an under-studied type of tumour that are rare but clinically challenging due to late detection, variable progression and frequent metastasis. The molecular basis of PNETs is not well understood and there are no prognostic markers to aid PNET clinical management. The overall aim of this study is to provide a comprehensive molecular characterization of PNETs to better understand disease progression and heterogeneity, and to devise clinically relevant subclasses. By integrating RNA-sequencing based transcriptome profiling and an innovative new technology for proteomic profiling of tumour specimens, their study will explore the proteogenomic landscape of PNETs. In addition to identifying disease classifiers, this study will lay the groundwork for further investigations of candidate biomarkers, potential driver mutations and therapeutic targets.